Dáil Éireann Debate, Thursday - 21 May 2026
353. Deputy Pádraig Rice asked the Minister for Health if her Department has assessed the adequacy and continuity of medicinal cannabis product availability under the Medical Cannabis Access Programme; if consideration is being given to expanding the range of approved products available to patients; and if she will make a statement on the matter. [38552/26]
View answerCannabis-based products used in the Medical Cannabis Access Programme are defined as "specified controlled drugs" in Statutory Instrument 262/2019, the Misuse Of Drugs (Prescription And Control Of Supply Of Cannabis For Medical Use) Regulations 2019 which also sets out the specifications in relation to Tetrahydrocannabinol (THC ) content, the main psychoactive extract of cannabis.
Any manufacturer or wholesaler is free to submit to the Health Products Regulatory Authority a Cannabis-based product for assessment for inclusion as a "specified controlled drug" in Schedule 1 of the 2019 Regulations.
